Foghorn Historical Income Statement
| FHTX Stock | USD 7.84 0.12 1.55% |
Historical analysis of Foghorn Therapeutics income statement accounts such as Depreciation And Amortization of 3.9 M or Interest Expense of 14 M can show how well Foghorn Therapeutics performed in making a profits. Evaluating Foghorn Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Foghorn Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Foghorn Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Foghorn Therapeutics is a good buy for the upcoming year.
Foghorn |
About Foghorn Income Statement Analysis
Foghorn Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Foghorn Therapeutics shareholders. The income statement also shows Foghorn investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Foghorn Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Foghorn Therapeutics. It is also known as Foghorn Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Cost Of Revenue
Cost of Revenue is found on Foghorn Therapeutics income statement and represents the costs associated with goods and services Foghorn Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most accounts from Foghorn Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Foghorn Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Foghorn Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn Therapeutics guide.At this time, Foghorn Therapeutics' Net Interest Income is fairly stable compared to the past year. Interest Income is likely to rise to about 11.1 M in 2024, whereas Selling General Administrative is likely to drop slightly above 19.7 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 7.5M | 3.3M | 3.5M | 3.9M | Interest Income | 2.6M | 5.7M | 10.6M | 11.1M |
Foghorn Therapeutics income statement Correlations
Click cells to compare fundamentals
Foghorn Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Foghorn Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | (45K) | 22K | 647K | 5.7M | 10.6M | 11.1M | |
| Interest Income | 495K | 1.0M | 2.6M | 5.7M | 10.6M | 11.1M | |
| Depreciation And Amortization | 1.2M | 5.5M | 7.5M | 3.3M | 3.5M | 3.9M | |
| Interest Expense | 540K | 979K | 1.9M | 11.6M | 13.3M | 14.0M | |
| Selling General Administrative | 6.7M | 11.2M | 21.7M | 30.7M | 32.4M | 19.7M | |
| Other Operating Expenses | 51.1M | 69.0M | 102.1M | 136.4M | 142.1M | 96.5M | |
| Operating Income | (51.1M) | (68.5M) | (100.7M) | (117.1M) | (107.9M) | (113.3M) | |
| Net Income From Continuing Ops | (51.1M) | (68.8M) | (101.3M) | (108.9M) | (103.2M) | (108.4M) | |
| Ebit | (51.1M) | (72.0M) | (103.7M) | (117.1M) | (107.9M) | (113.3M) | |
| Research Development | 44.4M | 57.7M | 80.3M | 105.6M | 109.7M | 76.8M | |
| Ebitda | (49.9M) | (66.5M) | (96.2M) | (113.8M) | (104.5M) | (109.7M) | |
| Total Operating Expenses | 51.1M | 69.0M | 102.1M | 136.4M | 142.1M | 96.5M | |
| Reconciled Depreciation | 693K | 1.3M | 3.2M | 3.3M | 3.4M | 2.3M | |
| Income Before Tax | (51.1M) | (68.8M) | (101.3M) | (108.9M) | (94.2M) | (98.9M) | |
| Total Other Income Expense Net | (44K) | (269K) | (586K) | 8.3M | 13.7M | 14.4M | |
| Net Income Applicable To Common Shares | (51.1M) | (68.8M) | (101.3M) | (108.9M) | (98.0M) | (102.9M) | |
| Net Income | (51.7M) | (69.8M) | (103.2M) | (108.9M) | (98.4M) | (103.3M) | |
| Income Tax Expense | 540K | 979K | 1.9M | (8.3K) | 4.2M | 4.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Foghorn Stock Analysis
When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.